Search This Blog

Thursday, April 24, 2025

Trump admin will boost Gulf of America oil production by 100K barrels/day under new drilling policy

 The Interior Department is helping to increase oil production in the newly renamed Gulf of America by 100,000 barrels per day under a new policy following President Trump’s executive order aimed at “Unleashing American Energy,” The Post can reveal.

Interior Secretary Doug Burgum announced that all offshore oil drilling in the Gulf will now be able to tap multiple reservoirs at the same time — and at far higher pressure than previously allowed — to immediately boost output by around 10%.

The department cited a September 2023 study from the University of Texas that found that over the next 30 years, up to 61% more oil can be produced than currently.

Interior Secretary Doug Burgum announced that all offshore oil drilling will now be able to tap multiple reservoirs at the same time — and at higher pressure than previously allowed — to immediately boost output by around 10%.AP

“This is a monumental milestone in achieving American energy dominance,” Burgum said in a statement.

“We’re delivering more American energy, more efficiently, and with fewer regulatory roadblocks. That means lower costs, more jobs, and greater security for American families and businesses as President Trump promised.”

Former President Joe Biden tried to kneecap the incoming administration by banning new offshore oil and gas drilling along most of America’s coast weeks before Trump returned to the White House — but the 47th president reversed that in a Day One executive rescission.

The Interior Department rule change will help boost oil production by 100,000 barrels per day under the policy shift pursuant to President Trump’s executive order aimed at “Unleashing American Energy.”Christopher Sadowski

“Climate extremism has exploded inflation and overburdened businesses with regulation,” Trump said in his official pronouncement reversing Biden’s policy, which made the “East coast, the eastern Gulf of Mexico, the Pacific off the coasts of Washington, Oregon, and California, and additional portions of the Northern Bering Sea in Alaska” off-limits to energy exploration.

Trump then signed another order declaring a national energy emergency, removing federal regulations that could “burden” domestic energy production.

“Climate extremism has exploded inflation and overburdened businesses with regulation,” Trump said in an official pronouncement of the executive order rescinding former President Joe Biden’s new oil and gas drilling banREUTERS

Now, through the Interior Department’s approval of a process known as “downhole commingling,” the number of oil reservoirs tapped concurrently by drillers will increase and the permitted pressure level of production will rise to 1500 psi from the earlier 200.

Key offshore oil and gas industry leaders suggested the technical changes, per the department’s press release.

Previously, the federal government had relied on a 2010 study to set oil production and pressure levels.

“This is a major win for domestic energy,” said Kenneth Stevens, principal deputy director of the Bureau of Safety and Environmental Enforcement.AP

“This is a major win for domestic energy,” said Kenneth Stevens, principal deputy director of the Bureau of Safety and Environmental Enforcement.

“Thanks to the tireless work of our technical experts and our industry partners, this advancement enables increased recovery from existing wells, reducing the cost per barrel and strengthening our nation’s energy independence.” 

Trump’s Day One orders on energy were aimed at tackling cumulative inflation that skyrocketed to 22% under Biden.

Trump renamed the Gulf of Mexico to the Gulf of America in a Day One executive order.AFP via Getty Images

“We’re going to make a lot of money from energy. We have more than anybody else,” he said when signing the actions Jan. 20.

Other executive actions taken that day included renaming the Gulf of Mexico to the Gulf of America — and restoring the name of Mount McKinley in Alaska, the highest peak in North America.

https://nypost.com/2025/04/24/us-news/trump-admin-will-increase-oil-production-in-gulf-of-america-by-100k-barrels-a-day-under-new-drilling-policy/

19-year-old Joseph Kling accused of sparking massive NJ wildfire, charged with arson

 A 19-year-old man has been charged with arson for allegedly sparking the massive wildfire in the New Jersey Pine Barrens that has torched 15,000 acres, prosecutors said.

Joseph Kling, of Ocean Township, allegedly started a bonfire in the vast Forked River Mountains Wilderness Area with wooden pallets that exploded out of control when he did not properly put it out, according to the Ocean County Prosecutor’s Office.

Kling was taken into custody at Ocean Township Police headquarters and taken to the Ocean County Jail where he is awaiting his detention hearing.

Joseph Kling, 19, was charged with arson in connection with the New Jersey wildfires.
15,000 acres have been damaged in the blaze.Getty Images

A column of smoke was first spotted from the Cedar Bridge Fire Tower in Barnegat Township around 9:45 a.m. on Tuesday, officials said.

The fire quickly spread out of control, forcing the evacuation of 5,000 residents of Ocean and Lacey Townships

As of Thursday morning, the fire had scorched roughly 15,000 acres and destroyed at least one commercial building.

The wildfire is currently 50% contained with 12 structures threatened, according to the latest update from the New Jersey Forest Fire Service.

5,000 residents were evacuated during the wildfires.AP

No injuries have been reported, and all evacuation orders have been lifted.

The massive blaze, one of the largest wildfires in the Garden State in decades, prompted an air quality advisory in New York City, Long Island, and Westchester and Rockland Counties through Thursday.

Officials estimate the fire might not be completely extinguished until at least Saturday.

https://nypost.com/2025/04/24/us-news/teen-accused-of-sparking-massive-nj-wildfire-charged-with-arson/

ResMed stock price target raised to $255 at RBC

 On Thursday, RBC Capital Markets adjusted its outlook on ResMed (NYSE:RMD), a company specializing in medical equipment for treating sleep disorders, by increasing its price target to $255 from the previous $247. The firm has opted to maintain a Sector Perform rating on the stock. 

The decision by analyst Craig Wong-Pan at RBC Capital follows ResMed’s third-quarter fiscal year 2025 results, which exhibited sustained robust growth in both revenue and earnings. The company’s revenue grew 9.38% over the last twelve months to $4.93 billion, with a healthy gross profit margin of 59%. Although the results met market expectations, the company’s announcement that its products would largely remain exempt from U.S. import tariffs stood out as a significant positive development.

RBC Capital’s revised price target is a reflection of minor adjustments to their forecasts, underpinned by an anticipated positive earnings growth trajectory for ResMed. The tariff exemptions are likely to contribute to the company’s continued financial health, providing a buffer against potential cost increases that could have arisen from tariff impositions.

The analyst’s commentary highlighted the strength of ResMed’s third-quarter performance, emphasizing the company’s solid growth momentum. "Robust growth and tariff exemptions; RMD’s 3Q25 result showed ongoing solid growth in revenue and earnings, albeit they were in line with market expectations. However, a positive update was that the company’s products should continue to be largely exempt from US import tariffs. We have made minor increases to our forecasts and maintain a positive earnings growth outlook for the stock. Our forecast changes increase our PT to $255 (from $247). SP rating maintained," Wong-Pan stated.

https://www.investing.com/news/analyst-ratings/resmed-stock-price-target-raised-to-255-at-rbc-capital-93CH-4002280

West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance



West Pharmaceutical Services (NYSE: WST) reported Q1 2025 financial results with net sales of $698.0 million, showing a 0.4% increase and 2.1% organic growth. The company's reported-diluted EPS was $1.23, down from $1.55 year-over-year, while adjusted-diluted EPS reached $1.45.

The company has raised its full-year 2025 guidance, with net sales now projected at $2.945-2.975 billion, up from previous $2.875-2.905 billion. The adjusted-diluted EPS guidance was increased to $6.15-6.35, incorporating estimated tariff costs of $20-25 million.

In Q1, Proprietary Products segment saw 0.6% growth to $563.0 million, while Contract-Manufactured Products declined 0.7% to $135.0 million. The company repurchased 550,281 shares for $133.5 million and declared a Q3 2025 dividend of $0.21 per share, payable August 6, 2025.

https://www.stocktitan.net/news/WST/west-announces-first-quarter-2025-results-increases-adjusted-diluted-7b9nq6uuglnt.html

NovoCure Surpasses Q1 Expectations

 NovoCure (NVCR 1.86%), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s estimate of $146 million.

GAAP earnings per share (EPS) were a negative $0.31, beating expectations of a negative $0.46 per share. The quarter was marked by robust patient growth and progress in clinical trials, though challenges in gross margins remain.

MetricQ1 2025Q1 2025 EstimateQ1 2024Y/Y Change
EPS (Non-GAAP)$(0.31)$(0.46)$(0.36)N/A
Revenue (GAAP)$155.0M$146.0M$138.5M+12.0%
Gross Margin (GAAP)75%N/A76%-1.0 pp
Active Patients on Therapy4,268N/A3,845+11.0%
Adjusted EBITDA (Non-GAAP)$(5.0)MN/A$(4.6)MN/A

Source: Analyst estimates for the quarter provided by FactSet.

Business Overview

Founded to bring a novel approach to cancer treatment, NovoCure utilizes TTFields therapy, which uses electric fields to disrupt cancer cell division. The company focuses on expanding its reach with current therapies and pursuing new indications. Regulatory approvals play a crucial role in its strategy, ensuring products reach patients globally. Current success hinges on growing patient numbers and progressing the research pipeline.

Recently, NovoCure has targeted multi-oncology indications—particularly in non-small cell lung cancer and pancreatic cancer—by leveraging its regulatory and R&D successes. The emphasis on securing reimbursement in new markets and maintaining financial health is equally pivotal.

The first quarter was marked by considerable revenue growth for NovoCure. GAAP revenue reached $155 million in Q1 2025, up 12% from the previous year, primarily due to an increase in active patients. In Q1 2025, the U.S., Germany, France, and Japan were significant markets, contributing $93.2 million, $18.7 million, $17.9 million, and $8.7 million, respectively. This expansion highlights a strengthened presence in existing markets.

Despite these gains, gross margins contracted to 75% in Q1 2025, down from 76% in Q1 2024. This was largely due to investments in launching new, higher-cost therapeutic arrays for NSCLC—non-small cell lung cancer—without full-fledged reimbursement support, slightly pressuring the gross margin in 2025.

https://www.fool.com/data-news/2025/04/24/novocure-surpasses-q1-expectations/

Merck Trims FY25 Adj. EPS Outlook

 While reporting financial results for the first quarter on Wednesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, trimmed its adjusted earnings guidance for the full-year 2025, while maintaining annual sales outlook.

The company said the outlook is revised to reflect the negative impact from anticipated one-time charge of approximately $0.06 per share related to license agreement with Hengrui Pharma.

The outlook also absorbs an estimated $200 million of additional costs for tariffs implemented to date.

For fiscal 2025, Merck now projects adjusted earnings in a range of $8.82 to $8.97 per share, lower than the prior guidance range of $8.88 to $9.03 per share. Sales are still expected between $64.1 billion and $65.6 billion.

On average, 23 analysts polled expect the company to report earnings of $8.94 per share on sales of $65.01 billion for the year. Analysts' estimates typically exclude special items.

https://www.rttnews.com/3531266/merck-trims-fy25-adj-eps-outlook-update.aspx